<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649971</url>
  </required_header>
  <id_info>
    <org_study_id>CR108515</org_study_id>
    <secondary_id>CNTO1959COR1001</secondary_id>
    <secondary_id>2019-001980-57</secondary_id>
    <nct_id>NCT03649971</nct_id>
  </id_info>
  <brief_title>A Study of Guselkumab in Participants With Familial Adenomatous Polyposis</brief_title>
  <official_title>A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects With Familial Adenomatous Polyposis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of treatment with guselkumab in
      participants with familial adenomatous polyposis (FAP) on rectal/pouch polyp burden.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Familial adenomatous polyposis (FAP) is the most common polyposis syndrome. It is autosomal
      dominant inherited disorder characterized by early onset of hundreds to thousands of
      adenomatous polyps throughout colon. If left untreated, this syndrome may develop colorectal
      cancer (CRC). Polyps from individuals with FAP display inflammatory features associated with
      activation of interleukin (IL) 23/IL 17/JAK/STAT3 pathway. This inflammation is thought to
      contribute to further mutagenesis, culminating in tumor development. Specifically, IL-23 is
      linked to tumor growth and progression in CRC. Guselkumab is a human immunoglobulin
      monoclonal antibody directed against p19 subunit of IL-23, specifically targets IL-23 and
      inhibits its interaction with IL-23 receptor, inhibiting IL 23 specific intracellular
      signaling and subsequent cell activation and cytokine production, which result in less
      inflammation and reduce tumor development. The clinical hypothesis of this study is that
      treatment with guselkumab will reduce rectal/pouch polyp burden compared with baseline in
      active arms compared with placebo. The study is designed to determine if guselkumab has
      clinical activity in colorectum and duodenum, by reducing number of polyps over a period of
      24 weeks. Participants will be randomized to 1 of 3 treatment arms (Guselkumab 100 mg
      [milligram] SC [subcutaneous], Guselkumab 300 mg SC, and placebo SC). Efficacy evaluations
      include rectal/pouch polyp burden assessment, biomarker analysis include discrete IL-23
      signaling effector proteins (IL-23R, pSTAT3, Il-17A) and safety evaluations will include
      monitoring of adverse events, laboratory tests, vital sign measurements, and physical
      examination. Safety will be monitored throughout study (up to Week 60).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Anticipated">March 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change from Baseline in Rectal/pouch Polyp Burden at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Percentage change from baseline in rectal/pouch polyp burden (sum of the polyp diameters) at Week 24 will be determined through endoscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change from Baseline in Number of Colorectal Polyps</measure>
    <time_frame>Baseline, Weeks 24 and 52</time_frame>
    <description>Percentage change from baseline in number of colorectal polyps will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change from Baseline in Number of J-pouch Polyps</measure>
    <time_frame>Baseline, Weeks 24 and 52</time_frame>
    <description>Percentage change from baseline in number of J-pouch polyps will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change from Baseline in J-pouch Polyp Burden</measure>
    <time_frame>Baseline, Weeks 24 and 52</time_frame>
    <description>Percentage change from baseline in J-pouch polyp burden (sum of polyp diameters) will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change from Baseline in Number of Duodenal Polyps</measure>
    <time_frame>Baseline, Weeks 24 and 52</time_frame>
    <description>Percentage change from baseline in number of duodenal polyps will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change from Baseline in Duodenal Polyp Burden</measure>
    <time_frame>Baseline, Weeks 24 and 52</time_frame>
    <description>Percentage change from baseline in duodenal polyp burden (sum of polyp diameters) will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage</measure>
    <time_frame>Baseline, Weeks 24 and 52</time_frame>
    <description>Change in InSiGHT stage will be determined. Various stages of InSiGHT staging system are defined as: Stage 0: 0-10 polyps, all less than (&lt;)5 millimeter (mm); Stage 1: 10-25 polyps, most &lt; 5 mm, none greater than (&gt;) 1 centimeter (cm); Stage 2: 10-25 polyps, any &gt; 1 cm, amenable to complete removal; Stage 3: &gt; 25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any evidence of High-Grade Dysplasia (HGD), even if completely excised; and Stage 4: &gt; 25 polyps amenable to complete removal, or any incompletely excised sessile polyp showing HGD, any invasive cancer).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Spigelman Stage Score</measure>
    <time_frame>Baseline, Weeks 24 and 52</time_frame>
    <description>Change in Spigelman stage score will be determined. Spigelman classification system measures risk of developing duodenal cancer in familial adenomatous polyposis (FAP). It has been classified in following stages- Stage 0 (0 points); Stage 1 (1-4 points); Stage 2 (5-6 points); Stage 3 (7-8 points); and Stage 4 (9-12 points). The total score ranges from 0 to 12. Points are accumulated for polyps' number, size, histology and severity of dysplasia. Stage 1 indicates mild disease, whereas stage 3-4 indicates severe duodenal polyposis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration of Guselkumab</measure>
    <time_frame>Weeks 0, 4, 8, 12, 16, 20, 24, 32, 40, and 48</time_frame>
    <description>Serum samples will be analyzed to determine trough concentrations of guselkumab using a validated specific, and sensitive method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-guselkumab Antibodies</measure>
    <time_frame>Weeks 0, 4, 8, 12, 16, 20, 24, 32, 40, and 48</time_frame>
    <description>Number of participants with Anti-guselkumab antibodies will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-guselkumab Antibodies Serum Titers</measure>
    <time_frame>Weeks 0, 4, 8, 12, 16, 20, 24, 32, 40, and 48</time_frame>
    <description>Serum samples will be screened for antibodies binding to guselkumab and the titer of confirmed positive samples will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>From Screening up to 60 Weeks</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Vital Sign Abnormalities as a Measure of Safety and Tolerability</measure>
    <time_frame>From Screening up to 52 Weeks</time_frame>
    <description>Number of participants with vital sign abnormalities will be reported. Vital signs includes temperature, pulse/heart rate, respiratory rate and blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinical Laboratory Abnormalities as a Measure of Safety and Tolerability</measure>
    <time_frame>From Screening up to 52 Weeks</time_frame>
    <description>Number of participants with clinical laboratory abnormalities will be reported. Blood samples for serum chemistry and hematology will be collected at predefined time points for clinical laboratory testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Changes to Baseline in Levels of Interleukin (IL)-23 Effector Proteins in Biopsy Tissue</measure>
    <time_frame>Baseline, Weeks 12, 24, and 52</time_frame>
    <description>Relative Changes to Baseline in levels of IL-23 effector proteins in biopsy tissue will be measured.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Adenomatous Polyposis Coli</condition>
  <arm_group>
    <arm_group_label>Guselkumab Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive guselkumab Dose 1 subcutaneous (SC), 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Guselkumab Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive guselkumab Dose 2 SC, 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo SC, 6 doses every 4 weeks from Week 0 to Week 20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guselkumab</intervention_name>
    <description>Guselkumab SC will be administered every 4 weeks.</description>
    <arm_group_label>Guselkumab Dose 1</arm_group_label>
    <arm_group_label>Guselkumab Dose 2</arm_group_label>
    <other_name>Tremfya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo SC will be administered every 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phenotypic familial adenomatous polyposis (FAP) with disease involvement of the
             colorectum by either genetic or clinical diagnosis: Adenomatous polyposis coli (APC)
             germline mutation with or without family history, or with greater than (&gt;)100 adenomas
             in large intestine and a family history of FAP, attenuated FAP is allowed. FAP
             phenotype post colectomy for polyposis with a family history of FAP may be allowed

          -  Post-colectomy or subtotal colectomy

          -  Polyps with a sum of diameters greater than or equal to (&gt;=)10 millimeter (mm) in the
             rectum or pouch on biopsy at screening

          -  A woman of childbearing potential must agree not to get pregnant during the study and
             at least 12 weeks after the last dose of study administration

          -  A woman must agree not to breast feed or donate eggs (ova, oocytes) during the study
             and for a period of 12 weeks after the last administration of study drug

        Exclusion Criteria:

          -  Prior use of any biologic therapy targeting interleukin (IL)-12/23, IL-17, or IL-23
             receptor

          -  Use of non-steroidal anti-inflammatory drugs other than aspirin during the study. The
             use 81 milligram (mg) of aspirin a day or 650 mg of aspirin per week is allowed

          -  Treatment with other FAP-directed drug therapy (including NSAID [Nonsteroidal
             anti-inflammatory drug] drugs), unless completes a 4-week washout period prior to
             randomization

          -  High grade dysplasia or cancer on biopsy at screening in GI tract (including stomach,
             duodenum, and colon/rectum/pouch)

          -  Duodenal, colorectal, or pouch polyp &gt;1 centimeter (cm) not excised at the screening
             evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University Of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wexner Medical Center at the Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot - CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>APHM Hopital Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Herford</name>
      <address>
        <city>Herford</city>
        <zip>32049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sourasky MC</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum Universiteit van Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. Heliodora Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Po</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pan American Center for Oncology Trials LLC</name>
      <address>
        <city>Río Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinic I Provincial de Barcelona</name>
      <address>
        <city>Madrid</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108515</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

